Menu Close

PERTHERA IN THE NEWS

GenomeWeb – Perthera’s Molecular Tumor Board Improves Patient Outcomes and Overcomes Barriers

GenomeWeb interviews Perthera CEO Gary Gregory and CMO Mike Pishvaian about the Perthera Platform’s proven results, the capabilities of Perthera’s molecular tumor board, and how precision medicine is changing the landscape of cancer care today.

Click to read the article here.

Perthera and PanCAN Publish Pivotal Paper in Lancet Oncology Highlighting the Importance of Selecting Treatments Based on Tumor Mutations

This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients. Patients who receive precision medicine live an average of one year longer than those who do not.

Click to read the breakthrough study abstract

Perthera and Lazarex Cancer Foundation Announce Partnership to Advance Precision Oncology Initiatives

Perthera and Lazarex are matching and enrolling patients in clinical trials through Lazarex’s IMPACT and CARE programs, by utilizing Perthera’s treatment-matching Artificial Intelligence (AI) technology to advance precision medicine for cancer patients.

How Perthera is Using AI and Molecular Data to Bring Precision Medicine to Oncology

Perthera CEO Gary Gregory talks with DocWire News to explain how Perthera’s Precision Oncology Platform is transforming precision medicine in healthcare today, with proven results and advanced technology.

Perthera, UVA, and EVMS team to study the Implementation and Clinical Impact of A Next Generation Precision Oncology Platform for Pancreatic Cancer Patients

Perthera, University of Virginia Health System (UVA) and Eastern Virginia Medical School (EVMS) Awarded $500,000 by Virginia Catalyst Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.

Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.

Molecular tumor profiling, which enables physicians to match patients to targeted therapies, is on the rise. Read the latest report published in the British Journal of Cancer.

ASCO 2019 Poster Presentation shows improved overall survival for advanced pancreatic cancer patients enrolled in the Know Your Tumor program.

Initial results from the KYT program demonstrated that 27% of pancreatic cancer patients harbor highly actionable molecular alterations, defined as biomarkers that predict for a high response rate to appropriately targeted therapies.

Perthera, Inc. Announces the Appointment of Gary L. Gregory as Chief Executive Officer, President and Board Member.

Mr. Gregory is an experienced CEO and Board Member with 30 years of progressively challenging responsibilities in the MedTech Sector.  His experience spans numerous companies and positions, including Executive Officer roles across several successful start-up companies, and leadership roles in Fortune 250 companies.

ASCO Daily News: Genomic and Transcriptomic Profiling Finds Potential Predictors and Therapeutic Targets in Pancreatic Cancer

Dr. Mike Pishvaian discusses results from Perthera and PanCAN’s Know Your Tumor study, presented as Abstract 191 at ASCO GI 2019 in San Francisco, CA.